Scholars Central

Conference abstractPublished 16 Nov 2015

Targeting sphingosine kinase 1 and apoptosis by Metformin to decrease tumor resistance to Adriamycin

Authors: Ahmed M Kabel

1Taif University, KSA 2Tanta University, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Solid Ehrlich carcinoma is a transplantable tumor model used in tumor studies. Adriamycin is a cytotoxic anthracycline antibiotic used in treatment of many types of cancer. Metformin is anti-diabetic drug and is under investigation for treatment of cancer. The aim of this work was to study the effect of each of adriamycin and metformin alone and in combination on solid Ehrlich tumor in mice. One hundred albino mice were divided into five equal groups: Control untreated group, SEC, SEC+adriamycin, SEC+metformin, SEC+adriamycin+metformin. Tumor volume, survival rate, tissue catalase, tissue reduced glutathione, tissue malondialdehyde, tissue sphingosine kinase 1 activity, tissue caspase 3 activity and tissue tumor necrosis factor alpha were determined. A part of the tumor was examined for histo-pathological and immune-histochemical study. Adriamycin or metformin alone or in combination induced significant increase in the survival rate, tissue catalase, reduced glutathione and tissue caspase 3 activity with significant decrease in tumor volume, tissue malondialdehyde, tissue sphingosine kinase 1 activity and tumor necrosis factor alpha and alleviated the histopathological changes with significant increase in p53 expression and apoptotic index compared to SEC group. The combination of adriamycin and metformin has a better effect than each of adriamycin or metformin alone against transplantable tumor model in mice.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ahmed M Kabel”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels